Centene (NYSE:CNC) FY Conference Summary Company Overview - **Company**: Centene Corporation - **Event**: Barclays Global Healthcare Conference - **Date**: March 10, 2026 Key Points Current Business Performance - Centene reaffirms adjusted EPS guidance of greater than $3 for 2026, with all three core business lines (Medicaid, Medicare, and Marketplace) on track so far [4][8] - Medicaid membership is expected to be approximately 3.5 million by the end of Q1 2026, down from 5.5 million in December 2025 [5][10] - The company is optimistic about the execution of ongoing trend initiatives impacting Medicaid and Medicare [4][8] Marketplace Dynamics - Membership in the Marketplace has decreased from 5.5 million in December to 3.6 million in February 2026, with expectations of reaching around 3.5 million by the end of the quarter [5][10] - The distribution of metal tiers shows a shift, with mid-30s% in Bronze, high teens% in Gold, and just under 50% in Silver [6][11] - Higher utilization patterns in specialty pharmacy are noted, particularly in the Silver tier, which may impact risk adjustment calculations [6][17] Risk Adjustment and Data Insights - Centene is tracking a Wakely report due at the end of March, which will provide insights into market contraction and membership distribution across metal tiers [7][13] - The company anticipates being in a net payable position for risk adjustment in 2026, but will remain conservative until full data is available [13][16] - The focus is on understanding therapeutic classes and disease states to inform risk adjustment strategies [17][18] Medicaid Trends and Initiatives - Medicaid cost trend for 2026 is expected to be around 4.5%, down from mid-6% in 2025 [19][20] - Centene is actively working on initiatives to combat fraud, waste, and abuse, which is estimated to account for 10% of all healthcare spending [22][23] - The company has developed 75 algorithms to identify suspect claims and is enhancing data sharing with state partners to improve program integrity [22][25] Medicare and Part D Insights - The individual PDP industry growth is expected to accelerate from 1% in 2025 to close to 3% in 2026, with Centene taking market share [31] - The company aims for a Part D margin of around 2% for 2026, with a focus on maintaining a favorable cost structure [32][33] - Medicare Advantage margins are projected to be slightly below break-even in 2026, with a goal of achieving break-even by 2027 [35][36] Capital Deployment Strategy - Centene plans no share repurchase in 2026, focusing instead on a partial redemption of $1 billion of 2027 notes to recalibrate debt levels [39][40] - The company is exploring ways to generate cash and monetize assets as part of its capital deployment strategy [40] Future Outlook on Medicaid Policy - Membership levels in Medicaid are expected to decline slightly due to tighter eligibility verification processes [41][42] - The impact of OB3 and work requirements will be assessed on a state-by-state basis, with guidance from CMS expected to influence future membership and margins [44][46] Additional Insights - The dialogue with CMS regarding Medicare rates has focused on ensuring that trend assumptions are reflective of current realities, particularly in light of COVID-19 data [36][37] - Centene is preparing for potential shifts in risk pools due to changes in Medicaid rates and eligibility requirements [46] This summary encapsulates the key insights and strategic directions discussed during the conference, highlighting Centene's performance, market dynamics, and future outlook in the healthcare sector.

Summary of Conference Call for Oscar Health Company Overview - **Company**: Oscar Health - **Industry**: Health Insurance Marketplace Key Points and Arguments 2025 Performance and 2026 Outlook - 2025 was a challenging year for Oscar Health and the broader marketplace due to misestimations of market morbidity, leading to losses for many carriers, including Oscar [2][3] - For 2026, Oscar Health has prepared for market shrinkage following the expiration of enhanced subsidies at the end of 2025, expecting a decrease in membership [2][3] - The company ended Open Enrollment with approximately **3.4 million members** and anticipates starting Q2 with about **3 million members**, accounting for expected attrition from passively enrolled members [2][3] Market Morbidity and Pricing Strategy - Oscar Health has priced for market morbidity driven by expected market shrinkage in the **20%-30% range**, but indications suggest it may be closer to **20%** [3][4] - The company has reaffirmed its guidance based on favorable membership statistics and improved stability compared to the previous year [4][5] Member Retention and Risk Assessment - Oscar Health has seen strong retention rates due to proactive measures taken over the past two years, including aggressive distribution engagement and strong plan designs [7][8] - The company has utilized industry tools to assess risk scores for new members, which generally tend to be younger and healthier than retaining members, leading to better profitability profiles over time [25][27] Risk Adjustment and Financial Health - Oscar Health expects to be a payer into the risk adjustment pool due to having healthier members than the average, which is a positive indicator for lower claims costs [31][32] - The company has raised **$400 million** in capital and entered into a **$475 million** revolver to ensure financial stability and support growth [96][97] Changes in Marketplace Dynamics - The marketplace is expected to shrink from **24 million to 20 million**, approximately a **20% decrease** [6] - Oscar Health has adapted to changes in the marketplace, including the disappearance of no-pay Silver plans with CSR, leading to a more balanced distribution among Bronze, Silver, and Gold plans [59][62] Individual Contribution Health Reimbursement Arrangements (ICHRA) - ICHRA allows employees to choose their health plans using employer-subsidized funds, promoting individualization and choice in healthcare [73][76] - The tax treatment for ICHRA subsidies is favorable for both employees and employers, making it an attractive option for companies [77][80] Cost Trends and Medical Expenses - Oscar Health experienced a **1% decline** in per member medical costs in the latter part of 2025, but anticipates a **12% trend** in medical expenses for 2026 due to market conditions and the expiration of subsidies [99][104] - The company has built its pricing strategy for 2026 based on past experiences and potential adverse effects from program integrity measures [106] Additional Important Insights - Oscar Health is supportive of CMS integrity measures aimed at reducing fraud in the marketplace, which they believe will ultimately benefit the system [36][41] - The company has shifted its membership mix significantly from Silver plans to a more balanced distribution across Bronze and Gold plans, which may affect historical performance metrics [64][68] This summary encapsulates the key discussions and insights from the conference call, highlighting Oscar Health's strategic positioning and outlook for the upcoming year.

Summary of Conference Call Company Overview - The discussion revolves around Oscar Health, a health insurance company, focusing on its performance in 2025 and expectations for 2026 [2][5]. Key Points 2025 Performance and 2026 Outlook - 2025 was a challenging year for Oscar and the broader marketplace due to misestimations of market morbidity, leading to losses [2]. - For 2026, Oscar has prepared for market shrinkage, expecting a decrease in membership from 3.4 million to approximately 3 million due to passively enrolled members not making payments [3][4]. - The company has priced for risks associated with market morbidity, anticipating a shrinkage in the 20%-30% range, but now expects it to be closer to 20% [3][4]. Membership and Retention - Oscar ended the open enrollment period with about 3.4 million members and expects to start the second quarter with around 3 million [2][3]. - The company has seen strong retention rates compared to peers, attributed to proactive measures taken over the past two years, including aggressive distribution engagement and strong plan designs [7][9]. Risk Management and Profitability - Oscar has implemented tools to assess risk scores for new members, which generally tend to be younger and healthier, leading to better profitability profiles in year two compared to year one [20][26]. - The company anticipates that the risk adjustment will be higher in the first half of the year, contributing to a 20% of premium revenue, compared to 18.5% the previous year [30]. Market Dynamics and Regulatory Environment - The marketplace is expected to shrink from approximately 24 million to 20 million members, with Oscar's peers experiencing greater attrition [6]. - Oscar has factored in potential impacts from regulatory changes and integrity measures introduced by CMS, which are expected to be implemented mid-year [34][43]. Metal Tier Changes - The company has shifted its membership mix from predominantly Silver plans to a more balanced distribution among Bronze, Silver, and Gold plans, with a significant increase in Gold plan enrollments [61][66]. - Historical performance metrics may not apply due to this shift in membership dynamics [64]. Individual Coverage Health Reimbursement Arrangement (ICHRA) - ICHRA allows employees to choose their health plans using employer-provided funds, promoting individualization and choice in healthcare [70][72]. - The tax treatment for ICHRA subsidies is favorable for both employees and employers, potentially leading to increased adoption in the future [74]. Financial Preparedness - Oscar has raised $400 million to prepare for growth and has established a $475 million revolver with top-tier banks, ensuring sufficient capital for expansion [95][96]. - The company utilizes quota share reinsurance, which covers approximately 55% of the capital required based on premiums, enhancing financial stability [97]. Cost Trends - The company experienced a per-member decline in medical costs in the latter part of the previous year, but anticipates a 12% trend in medical expenses for 2026 due to market morbidity and other factors [99][104]. Additional Insights - Oscar's proactive approach to risk management and market engagement positions it favorably compared to competitors, with a focus on maintaining a healthy member base and adapting to regulatory changes [7][34][43].

Financial Data and Key Metrics Changes - Total revenue for 2025 was reported at $11.7 billion, reflecting a 28% year-over-year increase [6][17] - The SG&A expense ratio improved by approximately 160 basis points to 17.5% [7][18] - The Medical Loss Ratio (MLR) increased by 570 basis points year-over-year to 87.4% [7][17] - The loss from operations for 2025 was approximately $396 million, a change of $454 million year-over-year [18][22] - The adjusted EBITDA loss for the full year was approximately $280 million, a change of $479 million year-over-year [18] Business Line Data and Key Metrics Changes - Membership grew to approximately 2 million in Q4 2025, a 22% increase year-over-year [15] - The company served 3.4 million members as of February 1, 2026, with expectations to start Q2 with around 3 million paid members, a 58% increase year-over-year [10][42] - Market share increased from 17% in 2025 to 30% in 2026 [10] Market Data and Key Metrics Changes - Overall market membership was reported at 23 million lives, a better-than-expected decline of 5% year-over-year [9] - The individual market is expected to experience a contraction of 20%-30% due to the expiration of enhanced premium tax credits [9][19] - The average member age is 38 years, approximately one year younger year-over-year [20] Company Strategy and Development Direction - The company aims to accelerate national Individual and Family Plans (IFP) and Individual Coverage Health Reimbursement Arrangements (ICHRA) expansion [13] - Oscar is focusing on creating lifestyle products with exceptional consumer experiences and driving operational excellence through AI [13][14] - The company has introduced new cost-effective Bronze and Gold plans to support consumers losing Enhanced Premium Tax Credits [11] Management's Comments on Operating Environment and Future Outlook - Management indicated that 2025 was a reset year for the industry, with higher market morbidity impacting dynamics [8] - The company expects a significant year-over-year improvement of nearly $750 million in earnings from operations in 2026 [7] - Management expressed confidence in returning to profitability in 2026, driven by disciplined pricing and innovative product offerings [22][26] Other Important Information - Oscar's investments in AI have led to a reduction in administrative costs by 160 basis points year-over-year while increasing membership [12] - The company ended 2025 with approximately $5.5 billion in cash and investments, including $414 million at the parent level [23] Q&A Session Summary Question: How does the company get comfort on new membership for 2026 and MLR projections? - Management indicated that they have significant information on renewing members and are leveraging third-party data for new members to project behaviors accurately [29][32] Question: Can you elaborate on 4Q utilization and its relation to 2026 expectations? - Utilization was modestly higher than expected, driven by members seeking care before losing subsidies [36] Question: What is the expected membership cadence following the 1Q grace period? - Higher churn is expected in the first quarter due to increased premiums, with a return to pre-ARPA churn patterns thereafter [44] Question: How does the mix of metal plans affect membership and profitability? - The company has seen a significant shift from Silver to Bronze and Gold plans, which may impact churn rates due to higher deductibles [47] Question: What are the key levers to achieving EBITDA profitability without enhanced subsidies? - Growth, AI efficiencies, and disciplined management of medical costs are key levers for profitability [73]

Financial Data and Key Metrics Changes - Total revenue for 2025 was reported at $11.7 billion, reflecting a 28% year-over-year increase [6][17] - The SG&A expense ratio improved by approximately 160 basis points to 17.5% [7][18] - The Medical Loss Ratio (MLR) increased by 570 basis points year-over-year to 87.4% [7][17] - The loss from operations for 2025 was approximately $396 million, a change of $454 million year-over-year [18][22] - The company expects a significant improvement in earnings from operations in 2026, projecting a range of $250 million to $450 million [22] Business Line Data and Key Metrics Changes - Membership grew to approximately 2 million in Q4 2025, a 22% increase year-over-year [15] - The company served 3.4 million members as of February 1, 2026, with expectations to start Q2 with around 3 million paid members, a 58% increase year-over-year [10][43] - Market share increased from 17% in 2025 to 30% in 2026 [10] Market Data and Key Metrics Changes - The overall market membership declined by 5% year-over-year to 23 million lives [9] - The company anticipates that many passively enrolled members will exit the market when grace periods expire, leading to a potential market contraction of 20%-30% [9][40] - The average member age is now 38 years, which is approximately one year younger than the previous year [20] Company Strategy and Development Direction - The company aims to accelerate national Individual and Family Plan (IFP) and Individual Coverage Health Reimbursement Arrangement (ICHRA) expansion [13] - Oscar introduced new cost-effective Bronze and Gold plans to support consumers losing Enhanced Premium Tax Credits [11] - The company is focusing on product innovation, launching several lifestyle offerings tailored to specific conditions [11][12] - Oscar's strategy includes leveraging AI to improve operational efficiency and member experience [12][13] Management's Comments on Operating Environment and Future Outlook - Management described 2025 as a reset year for the industry due to increased market morbidity and changes in market dynamics [8] - The company is positioned for strong top-line growth and margin expansion in 2026, with a disciplined pricing strategy [8][19] - Management expressed confidence in returning to profitability in 2026, with expectations of nearly $750 million improvement in earnings from operations [7][22] Other Important Information - The company ended 2025 with approximately $5.5 billion in cash and investments [23] - Oscar's capital position remains strong, with approximately $1 billion in capital surplus across its insurance subsidiaries [23] Q&A Session Summary Question: How does the company gain comfort on new membership for 2026 and MLR projections? - Management indicated that they have significant data on renewing members and are leveraging third-party data for new members to project behaviors accurately [29][32] Question: Can you elaborate on the utilization trends and expectations for 2026? - Management noted that utilization was modestly higher than expected in Q4, driven by members seeking care before losing subsidies [36] Question: What is the expected membership cadence following the grace period? - Management expects higher churn in Q1 due to increased premiums, estimating a drop from 3.4 million to 3 million paid members by the end of Q1 [44] Question: How does the mix of metal plans affect the company? - Management confirmed a significant shift from Silver to Bronze and Gold plans, which may lead to higher churn due to increased deductibles [47][66] Question: What are the key levers for achieving EBITDA profitability without enhanced subsidies? - Management highlighted growth, AI efficiencies, and disciplined pricing as key levers for profitability [73]

Summary of Agilon Health FY Conference Call (December 02, 2025) Company Overview - **Company**: Agilon Health (NYSE: AGL) - **Industry**: Healthcare Services, specifically focused on Medicare Advantage and value-based care models Key Points and Arguments Business Transition and Contracting Cycle - The company is undergoing a long-cycle business transition, with 50% of contracts open for the year, many being multi-year contracts [4][3] - Improvements made in the current year will not impact the profit and loss statement until the following year, indicating a longer economic cycle in the industry [4][3] Contracting Strategy - Agilon Health has focused on achieving appropriate economics for the value delivered to payer partners, with a disciplined approach to contracting [5][5] - In 2024, 60% of contracts included Part D risk, which is expected to decrease to 30% in 2025, with further improvements anticipated in 2026 [5][5] - The company is removing elements from contracts that introduce variability, such as Part D and supplemental benefits [6][6] Quality and Risk Adjustment - The company has a $25 million opportunity for quality performance in 2025, which is expected to double in 2026 [14][14] - Agilon is focusing on STAR scores, which have a long delay but are crucial for quality performance and financial incentives [14][14] Regulatory Landscape and Risk Management - The company is actively narrowing the risks it takes on, particularly concerning items outside its control, such as Part D and supplemental benefits [13][13] - Agilon has implemented a data pipeline to improve visibility into member-level premiums and costs, aiding in managing regulatory changes [16][16] Financial Outlook - The company expects to end 2025 with $300 million in cash and $100 million by the end of 2026, indicating good visibility into cash flow based on 2025 performance [66][66] - The benchmark rate for Medicare Advantage is expected to increase by approximately 9%, which is seen as a tailwind for the company [33][33] Market Dynamics and Growth Strategy - Agilon has paused growth initiatives for 2025 and 2026 to focus on improving profitability, despite strong demand from primary care partners [30][30] - The company has exited markets that do not present a near-term path to profitability, affecting approximately 29,000 members [30][30] Physician Partnerships - The company reports a high retention rate among physician partners, indicating strong relationships and engagement in driving improved economics [59][59] - There is ongoing demand for value-based care partnerships, despite macroeconomic challenges [62][62] Future Expectations - The company is optimistic about its positioning for 2026 and beyond, with plans to return to growth once a solid foundation is established [62][62] - Agilon is focused on executing strategies in 2025 that are expected to drive superior value in 2026 [77][77] Additional Important Insights - The regulatory environment is dynamic, and the company must remain nimble to adapt to changes, such as those in the ACO REACH program [20][20] - The discussions with payer partners have been constructive, with a focus on joint value creation and reducing volatility in contracts [36][36] - The company is working on improving cash and liquidity management, which is crucial for its operational model [37][37] This summary encapsulates the key points discussed during the Agilon Health FY Conference Call, highlighting the company's strategic focus, market dynamics, and financial outlook.

Financial Data and Key Metrics Changes - The company reported third quarter adjusted EPS of $0.50, exceeding previous expectations, and increased the full-year adjusted EPS forecast to at least $2 from $1.75 [4][5][25] - Premium and service revenue for the third quarter was $44.9 billion, with a GAAP loss per share of $13.50 due to a $6.7 billion non-cash goodwill impairment charge [25][32] - The adjusted effective tax rate was temporarily low, contributing approximately $0.10 to adjusted EPS, with an expected full-year adjusted tax rate of 20% to 21% [25][10] Business Line Data and Key Metrics Changes - The Medicaid segment achieved a third quarter HBR of 93.4%, aided by improved revenue from Florida's Children's Medical Services, which included a net $150 million positive revenue adjustment [10][25][26] - The Medicare segment's HBR was reported at 94.3%, reflecting typical cost patterns, with Medicare Advantage showing elevated medical cost trends consistent with expectations [18][25] - The Marketplace segment ended the quarter with approximately 5.8 million members, slightly better than expectations, despite experiencing medical cost pressure in September [15][25] Market Data and Key Metrics Changes - Medicaid membership stood at 12.7 million, with expectations of slight attrition in the coming quarters [27] - The company anticipates a 2025 Medicaid composite rate adjustment of roughly 5.5%, up from earlier estimates [8] - The Marketplace segment is preparing for potential market contraction in the high teens to mid-30s range due to the expiration of EAPTCs [40][45] Company Strategy and Development Direction - The company is focused on margin recovery over membership growth, particularly in the Marketplace segment, with pricing actions taken to support margin expansion in 2026 [39][51] - Continued advocacy for improved Medicaid rates and program changes is a priority, with efforts to manage high-cost drugs and enhance clinical management [11][14][57] - The company plans to provide detailed 2026 guidance in early February, emphasizing operational improvements and efficiency gains [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the overall performance of the business, despite challenges in the operating environment, and highlighted the importance of being responsible stewards of taxpayer dollars [24][60] - The company is closely monitoring trends in Medicaid and Marketplace utilization, with proactive measures in place to address potential challenges [10][37] - Management remains optimistic about the long-term viability of the individual health insurance market, despite uncertainties surrounding EAPTCs [17][40] Other Important Information - The company reported strong cash flow from operations of $1.4 billion in Q3, with unregulated cash on hand at $357 million [33] - The medical claims liability totaled $21.5 billion, representing 48 days in claims payable, an increase of one day compared to the previous quarter [33] - The company is prepared to harvest unrealized losses in Q4 to improve investment income trajectory for 2026 [31] Q&A Session Summary Question: How does the company ensure stability in the Marketplace amid competitor exits? - Management noted a slight uptick in utilization in September, correlating with national discussions on rate increases and EAPTCs, and emphasized prudent coverage for Q4 [36][37][40] Question: What efforts are in place to re-engage potential enrollees in the Marketplace? - The company is prepared to mobilize marketing efforts and broker relationships to recapture members who may not re-engage during open enrollment [42][44] Question: What is the outlook for Medicaid margins in 2026? - Management indicated that while 2026 is expected to be a trough year, they are focused on maintaining consistent profitability and margin improvement [68]

Summary of Centene Conference Call - September 11, 2025 Company Overview - **Company**: Centene Corporation (NYSE:CNC) - **Event**: Conference at the DB Healthcare Summit - **Speakers**: Sarah London (CEO), Drew Asher (CFO) Key Industry Insights Medicaid and Marketplace - **Full-Year Forecast**: Reaffirmed diluted EPS guidance of $1.75 for 2025 [3] - **Medicaid Results**: Positive results for July and August support the Health Benefit Ratio (HBR) improvement trajectory [4] - **Health Insurance Marketplace**: Successfully refiled rates covering 95% of membership for 2026, with most approvals expected by the end of the month [4][11] - **Risk Adjustment Headwinds**: $2.4 billion risk adjustment headwind and $200 million back half pressure remain in estimates [6][7] - **Utilization Trends**: Steady utilization in the Marketplace; updates on risk adjustment expected by the Q3 call [7] Medicare Segment - **Improvement Expectations**: Anticipated $700 million improvement in the Medicare segment, with STARS performance aligning with expectations [4] - **Break-Even Target**: On track to achieve break-even in Medicare Advantage by 2027 [4] - **Part D Performance**: Strong performance in Part D with 7.8 million members, below national benchmarks for low-income populations [71] Market Dynamics - **Sustainability of Marketplace**: The market is expected to remain sustainable even if enhanced subsidies expire, with potential growth from uninsured populations [17] - **Enrollment Projections**: Anticipated market contraction of 15% to 50% due to the expiration of enhanced Advanced Premium Tax Credits (APTCs) [64] Financial Performance and Guidance - **2026 Earnings Outlook**: Focus on margin recovery across Medicaid, Medicare Advantage, and Marketplace; specific guidance for 2026 not provided yet [58][60] - **Goodwill Evaluation**: Accelerated evaluation of goodwill due to market cap drop; no significant downstream impacts expected [74][75] - **Capital Deployment**: Priorities include funding organic growth, managing costs, and exploring share repurchase and M&A opportunities [76] Operational Strategies - **Cost Management**: Ongoing efforts to optimize discretionary spending and improve operational efficiency [78] - **Long-Term Margin Structure**: Confidence in margin improvement opportunities across all three business lines, with a focus on maintaining competitive margins [80] Additional Considerations - **Regulatory Changes**: Monitoring the impact of OB-3 and other regulatory changes on long-term margin structures [80] - **State Partnerships**: Positive engagement with state partners regarding rate increases and benefit design changes [39][40] This summary encapsulates the key points discussed during the Centene conference call, highlighting the company's strategic focus, financial outlook, and operational challenges within the healthcare industry.

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was reported at $2,900,000,000, representing a 29% increase year over year [7][18] - The medical loss ratio (MLR) increased by 12 points year over year to 91.1%, primarily due to an overall increase in average market morbidity [7][19] - The SG&A ratio improved by 90 basis points year over year to 18.7% [8][21] - The loss from operations was $230,000,000, a decrease of $298,000,000 year over year, while the adjusted EBITDA loss was $199,000,000 [8][22] - The company reaffirmed its 2025 guidance, projecting total revenue between $12,000,000,000 and $12,200,000,000 [8][24] Business Line Data and Key Metrics Changes - Membership grew to over 2,000,000, an increase of 28% year over year, driven by solid retention and above-market growth during open enrollment [19] - The second quarter MLR was impacted by a $316,000,000 increase in risk adjustment payable for 2025 due to higher ACA marketplace morbidity [19] Market Data and Key Metrics Changes - The latest risk adjustment data indicates a meaningful market-wide increase in morbidity in 2025, affecting all carriers with increases in mid to high single digits [9] - The company anticipates double-digit rate increases in the market for 2026 to address current morbidity pressures [10] Company Strategy and Development Direction - The company is focused on the individual market, believing it will stabilize in 2026 and is taking actions to mitigate current industry headwinds [8][12] - Oscar Health is acquiring early-stage assets to build a consumer marketplace, including a brokerage and a direct enrollment technology platform [13][14] - The company is launching a new ICRA product in partnership with Hy Vee Inc., targeting employers and employees in Des Moines, Iowa [15] Management's Comments on Operating Environment and Future Outlook - Management believes the individual market has significant long-term growth potential and is taking corrective actions to return to profitability in 2026 [16][27] - The company is confident in its capital position and expects to absorb the majority of forecasted losses through its excess capital [32][90] Other Important Information - The company is reducing its workforce in the second half of 2025, expecting to save approximately $60,000,000 in administrative costs for 2026 [12][27] - The company has a strong capital position with approximately $5,400,000,000 in cash and investments [22][90] Q&A Session Summary Question: Guidance on 2025 free cash flow and risk adjustment payable - Management confirmed a strong capital position and indicated that the majority of expected losses would be absorbed by excess capital [31] Question: Long-term targets for 2027 - Management reaffirmed the 5% margin target and stated that no changes to long-term forecasts are being made at this time [34] Question: Multiyear earnings levers - Management indicated that there are still opportunities to improve medical costs and administrative efficiencies [41] Question: Potential risk pool deterioration - Management expressed confidence that the risk pool would not deteriorate further and that they have factored risks into their pricing for 2026 [48] Question: Market stabilization assumptions for 2026 - Management stated that conservative assumptions have been built into the 2026 guidance, considering market morbidity shifts and program integrity impacts [52] Question: Membership shifts and retention - Management noted that improved membership retention and lower lapse rates contributed to membership growth, with no adverse selection observed [105]

Financial Data and Key Metrics Changes - The total revenue for Q2 2025 was $1.4 billion, down from $1.48 billion in Q2 2024, primarily due to lower risk adjustment contributions and unfavorable developments in Part D [29][30] - The medical margin for Q2 2025 was negative $53 million, compared to a positive $106 million in Q2 2024, driven by underperformance in the burden of illness program [30][32] - Adjusted EBITDA for Q2 2025 was negative $83 million, compared to negative $3 million in Q2 2024, reflecting the impact of lower risk adjustments and unfavorable prior period developments [32] Business Line Data and Key Metrics Changes - Medicare Advantage membership at the end of Q2 2025 was 498,000, down from 513,000 in Q2 2024, reflecting a measured approach to membership growth [28] - ACO REACH membership in Q2 2025 was 116,000, down from 132,000 in 2024, aligning with expectations [28] Market Data and Key Metrics Changes - The company reported a medical cost trend of 5.9% for Q2 2025, consistent with the previous year's trend of 6% [33] - The company has successfully reduced its exposure to Medicare Part D, with less than 30% of its membership carrying Part D risk in 2025 [34] Company Strategy and Development Direction - The company is focused on improving contract economics and bid visibility with payers, enhancing its data platform, and reducing variability in its business [35] - The leadership transition aims to strengthen execution and improve relationships critical to future success [11][12] - The company is committed to enhancing performance and positioning itself for sustainable value creation, particularly with the improved Medicare reimbursement model expected to take effect next year [15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2025 is a transition year with challenges that were more acute than previously expected, leading to underperformance [9][10] - The company expects to see the results of strategic initiatives in 2026, with a focus on improving operational and financial performance [16][17] - Management expressed confidence in the long-term value of the company's model and its ability to deliver significant growth opportunities [10][15] Other Important Information - The company has withdrawn its previously issued full-year 2025 financial guidance due to ongoing market uncertainties [34] - The leadership team is recalibrating the organization's culture to emphasize urgency, accountability, and performance [12] Q&A Session Summary Question: Clarification on potential positive PYD in Q3 and growth rate into 2026 - Management indicated that there was a small amount of favorable development on quality programs, but the significant negative developments were related to risk adjustment and Part D costs [39][40] Question: Call trends and cost trends development - Management confirmed that Q1 cost trends were around 6%, and Q2 trends were consistent with Q1, but July data was less complete [44] Question: 2026 class commentary and glide path strategy - Management stated that growth for 2026 is under review and they will be highly selective on future growth due to current business performance [57] Question: 2026 bidding insights - Management noted that payers are looking for improved economics as they head into 2026, and negotiations are ongoing [59][62] Question: CEO search criteria - The company is looking for a CEO with multi-market management capability, experience with primary care physicians, and strong operational rigor [67] Question: Quality incentives and their impact - Management highlighted that payers are increasingly willing to include more quality incentives in contracts, which could lead to increased dollars available for performance [72][73]